Bristol-Myers breaks ground on $200M Humacao expansion
Bristol-Myers Squibb Company today broke ground on a $200 million expansion of its facility in Humacao, Puerto Rico to add manufacturing capacity that will prepare the plant for the production of additional medicines. The project is expected to create 100 full-time jobs at the facility over time.
The plan encompasses approximately 190,000 square feet of new and renovated space to support the manufacture of cardiovascular medicines and medicines for type 2 diabetes. The project also includes the introduction of new, state-of-the-art manufacturing technology.
“Puerto Rico continues to be a key element of our manufacturing strategy. This additional investment further prepares our manufacturing network to support the growth of the company’s innovative, new medicines and robust pipeline, all dedicated to helping more patients prevail in their fight against serious diseases,” said Lou Schmukler, president, Global Manufacturing & Supply, Bristol-Myers Squibb.
In addition to investing $200 million in construction and equipment, the company expects to add about 100 new jobs through 2020. These positions include process engineers and operators, scientists, technicians and other skilled workers, and will be phased in as part of a multi-year plan to add manufacturing capacity to meet patient needs.
Gov. Alejandro García-Padilla was on hand for Friday’s announcement and touted the pharmaceutical’s commitment to Puerto Rico.
“Manufacturing is part of our economic backbone. We will strengthen it, focusing on those areas where we have competitive advantages, we will combine it with other activities, and we will diversify to promoting other industrial sectors,” García-Padilla said.
The Humacao expansion is the company’s second major investment in Puerto Rico in recent years. In 2009, Bristol-Myers Squibb completed a $200 million project to expand its site in Manati, Puerto Rico, to support the manufacture of biologic medicines.
”Our manufacturing sites in Puerto Rico play a vital role in our company’s BioPharma strategy and we are committed to maintaining their state-of-the-art capabilities and competitiveness,” says Ricardo Zayas, senior vice president, Pharmaceutical Manufacturing, Bristol-Myers Squibb.
Construction is expected to be completed in late 2015.